 JERUSALEM , Aug. 28, 2019 PRNewswire -- BiondVax Pharmaceuticals Ltd. NASDAQ: BVXV, a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ... 